Expert Interview
A second look: Discussing the current standard of care for celiac and new therapies in development such as TAK 101; an immune modifying nanoparticle designed to induce gluten-specific tolerance currently in development by Takeda Pharm
Ticker(s): TAKInstittuiton: Stanford University (formerly Univ of Chicago)
- Pediatric Gastroenterology specialist practicing in Chicago, IL with 16 years of experience.
- Clinical work and research have focused on a combination of cholestatic liver disease, nutrition, functional gastrointestinal disorders, and celiac disease
- Specializes in the diagnosis and treatment of digestive and liver diseases in children.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
